Center for Computational Molecular Biology, Brown University, Providence, RI, USA.
Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA.
Nat Microbiol. 2023 Oct;8(10):1911-1919. doi: 10.1038/s41564-023-01461-4. Epub 2023 Aug 28.
Diagnosis and treatment of Plasmodium falciparum infections are required for effective malaria control and are pre-requisites for malaria elimination efforts; hence we need to monitor emergence, evolution and spread of drug- and diagnostics-resistant parasites. We deep sequenced key drug-resistance mutations and 1,832 SNPs in the parasite genomes of 609 malaria cases collected during a diagnostic-resistance surveillance study in Ethiopia. We found that 8.0% (95% CI 7.0-9.0) of malaria cases were caused by P. falciparum carrying the candidate artemisinin partial-resistance kelch13 (K13) 622I mutation, which was less common in diagnostic-resistant parasites mediated by histidine-rich proteins 2 and 3 (pfhrp2/3) deletions than in wild-type parasites (P = 0.03). Identity-by-descent analyses showed that K13 622I parasites were significantly more related to each other than to wild type (P < 0.001), consistent with recent expansion and spread of this mutation. Pfhrp2/3-deleted parasites were also highly related, with evidence of clonal transmissions at the district level. Of concern, 8.2% of K13 622I parasites also carried the pfhrp2/3 deletions. Close monitoring of the spread of combined drug- and diagnostic-resistant parasites is needed.
需要对恶性疟原虫感染进行诊断和治疗,以有效控制疟疾,并为消除疟疾工作做准备;因此,我们需要监测耐药性寄生虫的出现、演变和传播。我们对 609 例在埃塞俄比亚进行诊断耐药性监测研究中采集的疟疾病例的寄生虫基因组中关键耐药突变和 1832 个单核苷酸多态性进行了深度测序。我们发现,8.0%(95%CI 7.0-9.0)的疟疾病例是由携带候选青蒿素部分耐药kelch13(K13)622I 突变的恶性疟原虫引起的,与由富含组氨酸蛋白 2 和 3(pfhrp2/3)缺失介导的诊断耐药寄生虫相比,这种突变在野生型寄生虫中较为少见(P=0.03)。单倍型分析表明,K13 622I 寄生虫彼此之间的关系明显比野生型更为密切(P<0.001),这与该突变的近期扩张和传播一致。pfhrp2/3 缺失的寄生虫也具有高度的相关性,在区一级存在克隆传播的证据。令人担忧的是,8.2%的 K13 622I 寄生虫也携带 pfhrp2/3 缺失。需要密切监测联合耐药性寄生虫的传播。